Alliance Voice CMS Concerns, The Truth About Alcohol is Revealed, and FDA Advisory Committee are Urged to Listen to Patients
People Living With Early Alzheimer's
Need President Biden’s Help
“CMS’ decision effectively cut off access for the vast majority of beneficiaries living with early Alzheimer's...”
For more than a year, the Centers for Medicare & Medicaid Services (CMS) has refused to cover an entire class of FDA-approved therapies for the treatment of mild cognitive impairment and early dementia due to Alzheimer's disease.
We at the Alliance for Aging Research work hard to provide you with the latest information on research, advocacy, and health policy topics. Now, you can access our monthly round-up directly from the source.
Podcast: The Truth About Alcohol with Dr. George F. Koob, Director of the National Institute on Alcohol Abuse and Alcoholism
April is Alcohol Awareness Month, a time to address the stigma around alcohol use disorder (AUD). Among the millions of Americans impacted, older adults remain at heightened risk of alcohol abuse due to a variety of environmental, medical, and social factors.
Alliance and Partners Urge FDA Advisory Committee to Listen to Alzheimer’s Patients and Families
The Alliance for Aging Research and the American Society of Consultant Pharmacists (ASCP) submitted a sign-on letter asking the FDA and two of its Advisory Committees to consider patient, family, and provider perspectives as they discuss a proposed expansion of the brexpiprazole label for agitation associated with Alzheimer's disease.